Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $110.00

Palvella Therapeutics (NASDAQ:PVLA) had its target price boosted by Chardan Capital from $73.00 to $110.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group boosted their price target on shares of Palvella Therapeutics from $66.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. TD Cowen upped their price objective on shares of Palvella Therapeutics from $65.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald lifted their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.67.

Palvella Therapeutics Stock Up 2.5%

Shares of NASDAQ PVLA traded up $1.93 during trading on Friday, reaching $79.76. 154,226 shares of the stock were exchanged, compared to its average volume of 116,135. The company has a market capitalization of $882.15 million, a price-to-earnings ratio of -21.04 and a beta of -0.05. The business’s 50-day moving average price is $66.13 and its 200 day moving average price is $42.98. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $83.00.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). As a group, sell-side analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Palvella Therapeutics

Several large investors have recently modified their holdings of PVLA. Clio Asset Management LLC bought a new stake in Palvella Therapeutics during the second quarter worth $2,063,000. Woodline Partners LP bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth $5,435,000. Goldman Sachs Group Inc. bought a new position in shares of Palvella Therapeutics during the 1st quarter worth approximately $533,000. Frazier Life Sciences Management L.P. lifted its holdings in Palvella Therapeutics by 5.5% during the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock worth $19,313,000 after acquiring an additional 36,120 shares during the period. Finally, Royce & Associates LP bought a new position in Palvella Therapeutics in the 1st quarter valued at $2,002,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.